Skip to main content
U.S. flag

An official website of the United States government

Notice of Special Interest (NOSI): Strengthening the HIV Prevention Continuum

Submitted by Anonymous (not verified) on

Notice Special Interest NOSI): Strengthening HIV Prevention Continuum Notice Number: NOT-MH-20-019 Key Dates Release Date: March 27, 2020 First Available Due Date: 07, 2020 Expiration Date: 08, 2023 Related Announcements PA-20-144, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R01 Clinical Trial Optional) PA-20-145, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R21 Clinical Trial Optional) PA-20-141, Formative Pilot Intervention Research Prevention Treatment HIV/AIDS R34 Clinical Trial Optional) PA-19-126, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed) PA-19-127, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) PA-19-116, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) PA-19-117, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) PA-19-118, Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) PA-19-119, Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) PA-19-052, NIH Small Research Grant Program Parent R03 Clinical Trial Allowed) PA-19-129, NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) PA-19-130, NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) PA-19-121, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Required) PA-19-122, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Allowed) PA-19-272, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PA-19-273, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Required) PA-19-270, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed PA-19-271, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Required PAR-19-051, Emerging Global Leader Award K43 Independent Clinical Trial Required) PAR-19-098, Emerging Global Leader Award K43 Independent Clinical Trial Allowed) PAR-17-485, NIMH Research Education Mentoring Program HIV/AIDS Researchers R25) PAR-18-714, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 - Clinical Trial Allowed) PAR-19-133, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 – Clinical Trial Required) PAR-19-134, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) PAR-19-135, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Required) PAR-19-283, Fogarty HIV Research Training Program Low-and Middle-Income Country Institutions D43 Clinical Trial Optional) PA-19-192, Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 Diversity) PA-19-188, Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) PA-18-403, Ruth L. Kirschstein National Research Service Award NRSA) Institutional Research Training Grant Parent T32) Issued National Institute Mental Health NIMH) Purpose National Institute Mental Health issuing Notice highlight interest receiving grant applications focused strengthening HIV prevention continuum understanding attendant challenges advancing novel interventions. Efforts stem HIV epidemic benefitted an expanding set evidence-based HIV prevention interventions. Behavioral HIV risk reduction approaches been complemented biomedical strategies such antiretroviral-based prevention mother-to-child transmission PMTCT), post-exposure prophylaxis PEP), pre-exposure prophylaxis PrEP), treatment prevention TasP). Novel long-acting HIV prevention modalities advancing through research development potential regulatory consideration, including vaginal rings, long-acting injectable PrEP, subdermal implants, broadly neutralizing antibodies, vaccine regimens. addition, multipurpose prevention technologies aim prevent pregnancy sexually transmitted infections, well HIV, also under development. Individuals may benefit proven HIV prevention modalities must maintain engagement the HIV prevention continuum optimum prevention benefit. HIV prevention continuum be represented a cycle begins HIV testing. Individuals test HIV negative should receive risk screening needs assessment identify preferred HIV prevention options, followed linkage relevant prevention services. Subsequent retention prevention services combine uptake, adherence, persistence prevention strategies best effect. cycle repeats renews through regular HIV testing. Substantial challenges evident across lifecycle the HIV prevention continuum. people not receive regular HIV testing according recommended schedules. Access prevention counseling assessment be limited. PrEP implementation advanced, successful identification, engagement, retention individuals may benefit PrEP proven challenging. Sharp racial/ethnic, age, gender-based disparities evident PrEP uptake use. Proven interventions support PrEP adherence persistence remain scant -- while future long-acting formulations assist adherence -- challenges engagement retention prevention services remain. meet challenges, NIMH calls research will improve scientific understanding gaps challenges the HIV prevention continuum, well studies develop test interventions designed strengthen HIV prevention continuum prevention outcomes. Areas Research Interest Areas programmatic interest include, are limited to: Studies identify gaps targets the HIV prevention continuum associated determinants inform intervention development Studies improve regular HIV testing according recommended schedules Studies decision support tools help individuals, couples, clinicians informed choices HIV prevention options Studies strategies promote PrEP care engagement uptake among individuals substantial HIV risk Studies improve retention biomedical HIV prevention services Studies develop test interventions improve PrEP adherence persistence, well methods support PrEP during risk intervals Studies reduce racial/ethnic, age, gender-related disparities PrEP uptake use Studies better understand overcome challenges faced mobile populations, such migrants, displaced people, individuals are homeless marginally housed, accessing benefitting HIV care preventive services Studies develop test methods enable medical providers identify counsel those may benefit PrEP, to increase PrEP prescriptions where appropriate Studies advance innovative approaches PrEP delivery Studies develop test behavioral, provider, healthcare systems interventions facilitate uptake use long-acting HIV prevention regimens multipurpose prevention technologies MPTs) Studies integrate behavioral social science research development testing next generation HIV prevention products, including long-acting prevention products multipurpose prevention technologies MPTs), facilitate effective future implementation. Studies advance practice HIV treatment prevention its impact Application Submission Information notice applies due dates or after 7, 2020 subsequent receipt dates through 8, 2023. Submit applications this initiative using of following funding opportunity announcements FOAs) any reissues these announcement through expiration date this notice. PA-20-144, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R01 Clinical Trial Optional) PA-20-145, Innovations HIV Prevention, Testing, Adherence Retention Optimize HIV Prevention Care Continuum Outcomes R21 Clinical Trial Optional) PA-20-141, Formative Pilot Intervention Research Prevention Treatment HIV/AIDS R34 Clinical Trial Optional) PA-19-126, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Allowed) PA-19-127, Mentored Research Scientist Development Award Parent K01 - Independent Clinical Trial Required) PA-19-116, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Required) PA-19-117, Mentored Clinical Scientist Research Career Development Award Parent K08 Independent Clinical Trial Allowed) PA-19-118,Mentored Patient-Oriented Research Career Development Award Parent K23 Independent Clinical Trial Required) PA-19-119, Mentored Patient-Oriented Research Career Development Award Parent K23 – Independent Clinical Trial Allowed) PA-19-052, NIH Small Research Grant Program Parent R03 Clinical Trial Allowed) PA-19-129, NIH Pathway Independence Award Parent K99/R00 Independent Clinical Trial Required) PA-19-130, NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed) PA-19-121, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Required) PA-19-122, Midcareer Investigator Award Patient-Oriented Research Parent K24 Independent Clinical Trial Allowed) PA-19-272, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PA-19-273, PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Required) PA-19-270,PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed PA-19-271, PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Required PAR-19-051, Emerging Global Leader Award K43 Independent Clinical Trial Required) PAR-19-098, Emerging Global Leader Award K43 Independent Clinical Trial Allowed) PAR-17-485, NIMH Research Education Mentoring Program HIV/AIDS Researchers R25) PAR-18-714, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 - Clinical Trial Allowed) PAR-19-133, Academic Research Enhancement Award Undergraduate-Focused Institutions R15 – Clinical Trial Required) PAR-19-134, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) PAR-19-135, Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Required) PAR-19-283, Fogarty HIV Research Training Program Low-and Middle-Income Country Institutions D43 Clinical Trial Optional) PA-19-192, Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196, Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 Diversity) PA-19-188, Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) PA-18-403, Ruth L. Kirschstein National Research Service Award NRSA) Institutional Research Training Grant Parent T32) instructions the SF424 R&R) Application Guide and funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include ldquo;NOT-MH-20-019” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. nbsp; Inquiries Please direct inquiries to: Please direct inquiries the Scientific/Research, Peer Review, Financial/Grants Management contacts Section VII the listed funding opportunity announcements. Scientific/Research Contact(s) Michael J. Stirratt Ph.D.National Institute Mental Health NIMH) Telephone: 240-627-3875 Email: stirrattm@nih.gov Peer Review Contact(s) Examine eRA Commons account review assignment contact information information appears weeks after submission due date). Financial/Grants Management Contact(s) Rita Sisco National Institute Mental Health NIMH) Telephone: 301-443-2805 Email: siscor@mail.nih.gov nbsp;

Funding Number
NOT-MH-20-019
Funding Activity Code
05/08/2023
Release Date
Expiration Date
Organization
NIMH
Division
DCM

This page last reviewed on August 10, 2021